Matrix metalloproteases in bronchoalveolar lavage fluid of patients with type III Pseudomonas aeruginosa pneumonia

Journal of Infection

Volumn 59, Issue 1, 2009, Pages 49-55

  El Solh, Ali A ^a,b   Amsterdam, Daniel ^c   Alhajhusain, Ahmad ^a,b   Akinnusi, Morohonfolu E ^a   Saliba, Ranime G ^a   Lynch, Susan V ^d   Wiener Kronish, Jeanine P ^e  

^a VA WESTERN NEW YORK HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c ERIE COUNTY MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Exotoxin; Metalloproteinases; Pseudomonas aeruginosa; Ventilator associated pneumonia

Indexed keywords

ALPHA 2 MACROGLOBULIN; ANTIBIOTIC AGENT; ENDOTOXIN; GELATINASE B; NEUTROPHIL COLLAGENASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HUMAN; LUNG LAVAGE; MALE; PHENOTYPE; PROGNOSIS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS PNEUMONIA; SURVIVAL RATE; TYPE III SECRETION SYSTEM; VENTILATOR ASSOCIATED PNEUMONIA;

AGED; BRONCHOALVEOLAR LAVAGE FLUID; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 8; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; MIDDLE AGED; PNEUMONIA, BACTERIAL; PNEUMONIA, VENTILATOR-ASSOCIATED; PSEUDOMONAS INFECTIONS; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 67649920897     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2009.05.004     Document Type: Article

References (38)

1. Rossolini G.M., and Mantengoli E. Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa. Clin Microbiol Infect 11 (2005) 17-32
2. Rello J. Bench-to-bedside review: therapeutic options and issues in the management of ventilator-associated bacterial pneumonia. Crit Care 9 (2005) 259-265
3. LaBaer J., Qiu Q., Anumanthan A., Mar W., Zuo D., Murthy T.V., et al. The Pseudomonas aeruginosa PA01 gene collection. Genome Res 14 (2004) 2190-2200
4. Mota L., Sorg I., and Cornelis G. Type III secretion: the bacteria-eukaryotic cell express. FEMS Microbiol Lett 252 (2005) 1-10
5. Roy-Burman A., Savel R.H., Racine S., Swanson B.L., Revadigar N.S., Fujimoto J., et al. Type III protein secretion is associated with death in lower respiratory and systemic Pseudomonas aeruginosa infections. J Infect Dis 183 (2001) 1767-1774
6. Hauser R.A., Cobb E., Bodi M., Mariscal D., Vallés J., Engel J.N., et al. Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Crit Care Med 30 (2002) 521-528
7. El Solh A.A., Akinnusi M.E., Wiener-Kronish J.P., Lynch S.V., Pineda L.A., and Szarpa K. Persistent infection with Pseudomonas aeruginosa in ventilator associated pneumonia. Am J Respir Crit Care Med 178 (2008) 513-519
8. O'Connor C.M., and FitzGerald M.X. Matrix metalloproteases and lung disease. Thorax 49 (1994) 602-609
9. Corbel M., Lagente V., and Boichot E. Pulmonary inflammation and tissue remodeling: role of metalloproteinases. Eur Respir Rev 10 (2000) 260-263
10. Chubinskaya S., Huch K., Mikecz K., Cs-Szabo G., Hasty K.A., Kuettner K.E., et al. Chrondrocyte matrix metalloproteinase-8. Upregulation of neutrophil collagenase by interleukin-1 beta in human cartilage from knee and ankle joints. Lab Invest 74 (1996) 232-240
11. Prikk K., Maisi P., Pirila E., Sepper R., Salo T., Wahlgren J., et al. In vivo collagenase-2 (MMP-8) expression by human bronchial epithelial cells and monocytes/macrophages in bronchiectasis. J Pathol 194 (2001) 232-238
12. Gomez D.E., Alonso D.F., Yoshiji H., and Thorgeirsson U.P. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 74 (1997) 111-122
13. Bode W., Fernandez-Catalan C., Nagase H., and Maskos K. Endoproteinase-protein inhibitor interactions. APMIS 107 (1999) 3-10
14. Hartog C., Wermelt J., Sommerfeld C., Eichler W., Dalhoff K., and Braun J. Pulmonary matrix metalloproteinase excess in hospital-acquired pneumonia. Am J Respir Crit Care Med 167 (2003) 593-598
15. El Solh A.A., Choi G., Schultz M.J., Pineda L.A., and Mankowski C. Clinical and hemostatic responses to treatment in ventilator-associated pneumonia: role of bacterial pathogens. Crit Care Med 35 (2007) 490-496
16. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia: official statement of ATS and IDSA. Am J Respir Crit Care Med 171 (2005) 388-416
17. Knaus W.A., Draper E.A., Wagner D.P., and Zimmerman J. APACHE II: a severity of disease classification system. Crit Care Med 13 (1985) 818-829
18. Pugin J., Auckenthaler R., Mili N., Janssens J.P., Lew P.D., and Suter P.M. Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and non-bronchoscopic blind bronchoalveolar lavage fluid. Am Rev Respir Dis 143 (1991) 1121-1129
19. Nicas T.I., and Iglewski B.H. Isolation and characterization of transposon-induced mutants of Pseudomonas aeruginosa deficient in production of exoenzyme S. Infect Immun 45 (1984) 470-474
20. Greenberger P.A. Immunologic aspects of lung diseases and cystic fibrosis. JAMA 278 (1997) 1924-1930
21. Betsuyaku T., Nishimura M., Takeyabu K., Tanino M., Venge P., Xu S., et al. Neutrophil granule proteins in bronchoalveolar lavage fluid from subjects with subclinical emphysema. Am J Respir Crit Care Med 159 (1999) 1985-1991
22. Suga M., Iyonaga K., Okamoto T., Gushima Y., Miyakawa H., Akaike T., et al. Characteristic elevation of matrix metalloproteinase activity in idiopathic interstitial pneumonias. Am J Respir Crit Care Med 162 (2000) 1949-1956
23. Finck-Barbançon V., Goranson J., Zhu L., Sawa T., Wiener-Kronish J.P., Fleiszig S.M., et al. ExoU expression by Pseudomonas aeruginosa correlates with acute cytotoxicity and epithelial injury. Mol Microbiol 25 (1997) 547-557
24. Dacheux D., Attree I., Schneider C., and Toussaint B. Cell death of human polymorphonuclear neutrophils induced by a Pseudomonas aeruginosa cystic fibrosis isolate requires a functional type III secretion system. Infect Immun 67 (1999) 6164-6167
25. Diaz M.H., Shaver C.M., King J.D., Musunuri S., Kazzaz J.A., and Hauser A.R. Pseudomonas aeruginosa induces localized immunosuppression during pneumonia. Infect Immun 76 (2008) 4414-4421
26. Gaggar A., Li Y., Weathington N., Winkler M., Kong M., Jackson P., et al. Matrix metalloprotease-9 dysregulation in lower airway secretions of cystic fibrosis patients. Am J Physiol Lung Cell Mol Physiol 293 (2007) L96-L104
27. Kumagai K., Ohno I., Okada S., Ohkawara Y., Suzuki K., Shinya T., et al. Inhibition of matrix metalloproteinases prevents allergen-induced airway inflammation in a murine model of asthma. J Immunol 162 (1999) 4212-4219
28. Shapiro S.D. Elastolytic metalloproteinases produced by human mononuclear phagocytes. Potential roles in destructive lung disease. Am J Respir Crit Care Med 150 (1994) S160-S164
29. Paul R., Lorenzl S., Koedel U., Sporer B., Vogel U., Frosch M., et al. Matrix metalloproteinases contribute to the blood-brain barrier disruption during bacterial meningitis. Ann Neurol 44 (1998) 592-600
30. Lindberg R.L.P., Sorsa T., Tervahartiala T., Hoffmann F., Mellanen L., Kappos L., et al. Gelatinase B [matrix metalloproteinase (MMP)-9] and collagenases (MMP-8/-13) are upregulated in cerebrospinal fluid during aseptic and bacterial meningitis in children. Neuropathol Appl Neurobiol 32 (2006) 304-317
31. Steinberg J., Halter J., Schiller H., Gatto L., Carney D., Lee H.M., et al. Chemically modified tetracycline prevents the development of septic shock and acute respiratory distress syndrome in a clinically applicable porcine model. Shock 24 (2005) 348-356
32. Bottcher T., Spreer A., Azeh I., and Gerber J. Matrix metalloproteinase-9 deficiency impairs host defense mechanisms against Streptococcus pneumoniae in a mouse model of bacterial meningitis. Neurosci Lett 338 (2003) 201-204
33. Stockley R.A. Neutrophils and protease/antiprotease imbalance. Am J Respir Crit Care Med 160 (1999) S49-S52
34. Renckens R., Roelofs J., Florquin S., de Vos A.F., Lijnen H.R., van't Veer C., et al. Matrix metalloproteinase-9 deficiency impairs host defense against abdominal sepsis. J Immunol 176 (2006) 3735-3741
35. Tang J., Liu J., Zhou C., Alexander J.S., Nanda A., Granger D.N., et al. MMP-9 deficiency enhances collagenase-induced intracerebral hemorrhage and brain injury in mutant mice. J Cereb Blood Flow Metab 24 (2004) 1133-1145
36. Van Lint P., Wielockx B., Puimege L., Noël A., López-Otin C., and Libert C. Resistance of collagenase-2 (matrix metalloproteinase-8)-deficient mice to TNF-induced lethal hepatitis. J Immunol 175 (2005) 7642-7649
37. Balbin M., Fueyo A., Tester A.M., Pendás A.M., Pitiot A.S., Astudillo A., et al. Loss of collagenase-2 confers increased skin tumor susceptibility to male mice. Nat Genet 35 (2003) 252-257
38. Gutierrez-Fernandez A., Inada M., Balbin M., Fueyo A., Pitiot A.S., Astudillo A., et al. Increased inflammation delays wound healing in mice deficient in collagenase-2 (MMP-8). FASEB J 21 (2007) 2580-2591